ClinicalTrials.gg
Enrolling by invitationNCT05762055Updated May 13, 2026

Prospective Comparative Analysis of ACDF vs Fusion Interbody Cages With nanoLOCK Osseointegrative Technology

An interventional study of Titan nanoLOCK interbody cage and ACDF interbody cage in Cervical Radiculopathy and Cervical Myelopathy, sponsored by University of Texas Southwestern Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.

Planned enrollment
22nd of 106
200 · median 78
Started
2024
with 2 others
No phase
63 of 126
17 open now
Primary completion
2026-05
later than 8 of 36 live
Registered
109th of 126
by date

Among the 126 studies in Radiculopathy with a site in United States, this one is the 22nd largest by planned enrollment of the 106 interventional ones that give a count, is one of 3 that started in 2024, is one of 63 with no phase, reaches primary completion later than 8 of the 36 other live ones, and was the 109th registered.

Radiculopathy

484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

Study team will plan a prospective, randomized control trial using our institution's spine clinical outcomes registry. Eligible patients undergoing ACDF (see inclusion criteria listed below) will be randomized to an Intervention or Control Group, which will differ according to the interbody cage used during the procedure. In the Intervention Group (100 patients), Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted at each treated level. In the Control Group (100 patients), patients will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology. Interbody cages used in the Control Group (along with the decision to apply anterior plate fixation) will be determined according to surgeon preference. There will be no blinding to the type of implant used. Standard demographic and procedural variables will be collected for all patients (including history of diabetes, tobacco, use, prior use of oral corticosteroids, number of levels fused, and presence of bicortical screw placement). Clinical and radiographic outcomes in the Intervention and Control Groups will be directly compared.

Read the detailed description

Aim 1: Examine the effect of nanoLOCK technology on rates of postoperative dysphagia after ACDF.

Aim 2: Evaluate the effect of nanoLOCK technology on radiographic fusion.

Aim 3: Evaluate how nanoLOCK technology influences the development of radiographic adjacent segment disease.

03

Conditions studied

  • Cervical Radiculopathy
  • Cervical Myelopathy

Keywords

  • spine
  • cervical
  • discectomy
  • bony fusion
  • dysphagia
  • radiographic fusion
  • radiographic adjacent segment disease
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 18 years of age or older
  • Subjects undergoing ACDF surgery for degenerative pathology (one, two or three levels)
  • Subjects with no prior history of cervical spine surgery
  • Subjects with complete/usable data

Exclusion criteria

Exclusion Criteria:

  • Subjects under the age of 18
  • Subjects not undergoing ACDF surgery
  • Subjects with prior cervical spine surgery
  • Subjects with cervical neoplastic or infectious disease pathology
  • Subjects with cervical trauma pathology
  • ACDF performed at C2-3
  • Subjects with incomplete/unusable data
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted for participants in this group

    Device: Titan nanoLOCK interbody cage

  • Experimental
    Control Group

    Participants in this arm will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology.

    Device: ACDF interbody cage

Interventions

  • DeviceTitan nanoLOCK interbody cage

    Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology

    Also known as: Titan nanoLOCK®

  • DeviceACDF interbody cage

    Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology

06

What researchers measure

Primary outcomes

  1. Number of patient reported dysphagia events measured by Eat-10 assessment tool

    Number of patient reported dysphagia events (incidence \& severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem.

    Time frame: Postoperative at Day 1

  2. Number of patient reported dysphagia events measured by Eat-10 assessment tool

    Number of patient reported dysphagia events (incidence \& severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem.

    Time frame: 2 weeks following surgery

  3. Number of patient reported dysphagia events measured by Eat-10 assessment tool

    Number of patient reported dysphagia events (incidence \& severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem.

    Time frame: 3 months following surgery

  4. Number of patient reported dysphagia events measured by Eat-10 assessment tool

    Number of patient reported dysphagia events (incidence \& severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem.

    Time frame: 6 months following surgery

  5. Number of patient reported dysphagia events measured by Eat-10 assessment tool

    Number of patient reported dysphagia events (incidence \& severity ) is measured by Eating Assessment Tool (EAT-10) post surgery at day1 which is self-administered, symptom-specific outcome instrument for dysphagia. It consists of ten statements that a patient rates on a scale of 0-4, with 0=no problem to 4=severe problem.

    Time frame: 12 months following surgery

  6. Dysphagia as measured by SWAL-QOL assessment tool

    Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best).

    Time frame: Postoperative at day 1

  7. Dysphagia as measured by SWAL-QOL assessment tool

    Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best).

    Time frame: 2 weeks following surgery

  8. Dysphagia as measured by SWAL-QOL assessment tool

    Dysphagia is measured by SWAL-QOL assessment tool which is used in understanding quality of life in swallowing disorders. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best).

    Time frame: 3 months following surgery

  9. Dysphagia as measured by SWAL-QOL assessment tool

    Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best).

    Time frame: 6 months following surgery

  10. Dysphagia as measured by SWAL-QOL assessment tool

    Dysphagia is measured by SWAL-QOL assessment tool which is designed to find out how one's swallowing problem has been affecting their day-to-day quality of life. Scoring in each domain is calculated by the sums of scores for each item expressed as a percentage of the maximum possible domain score. A total SWAL-QOL score is derived by summing each domain score and dividing by 10 giving a total SWAL-QOL score that ranges between 0 and 100 (worst-best).

    Time frame: 12 months following surgery

  11. Degree of radiographic fusion

    Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine.

    Time frame: 6 weeks following surgery

  12. Degree of radiographic fusion

    Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine.

    Time frame: 3 months following surgery

  13. Degree of radiographic fusion

    Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine.

    Time frame: 6 months following surgery

  14. Degree of radiographic fusion

    Degree of radiographic fusion is measured by quantifying (count of) the presence of bony trabeculae crossing the interface between the implant and adjacent levels as obtained via CT of the cervical spine.

    Time frame: 12 months following surgery

  15. Incidence of radiographic adjacent segment disease

    Incidence of radiographic adjacent segment disease is measured by quantifying (number of occurrence) the following parameters (i.e., Suprajacent and/or subjacent level kyphosis; Vacuum disc phenomenon at adjacent level discs; Adjacent level compression deformity) on postoperative imaging

    Time frame: 6 months following surgery

  16. Incidence of radiographic adjacent segment disease

    Incidence of radiographic adjacent segment disease is measured by quantifying (number of occurrence) the following parameters (i.e., Suprajacent and/or subjacent level kyphosis; Vacuum disc phenomenon at adjacent level discs; Adjacent level compression deformity) on postoperative imaging

    Time frame: 12 months following surgery

Secondary outcomes

  1. Percentage of participants experiencing neck pain

    Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable.

    Time frame: Baseline (Pre-op)

  2. Percentage of participants experiencing neck pain

    Percentage of participants experiencing neck pain is assessed using Vissual Analogue Scale (VAS)-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable.

    Time frame: 6 weeks following surgery

  3. Percentage of participants experiencing neck pain

    Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable.

    Time frame: 3 months following surgery

  4. Percentage of participants experiencing neck pain

    Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable.

    Time frame: 6 months following surgery

  5. Percentage of participants experiencing neck pain

    Percentage of participants experiencing neck pain is assessed using VAS-neck questionnaire. Possible scores range from 0-10, where 0=no pain and 10= worst pain imaginable.

    Time frame: 12 months following surgery

  6. Percentage of participants showing functional improvement

    Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst.

    Time frame: Baseline (Pre-op)

  7. Percentage of participants showing functional improvement

    Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst.

    Time frame: 6 weeks following surgery

  8. Percentage of participants showing functional improvement

    Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst.

    Time frame: 3 months following surgery

  9. Percentage of participants showing functional improvement

    Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst.

    Time frame: 6 months following surgery

  10. Percentage of participants showing functional improvement

    Percentage of participants showing functional improvement is assessed using Neck Disability Index (NDI) questionnaire. Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst.

    Time frame: 12 months following surgery

  11. Number of participants who experienced overall complications

    Overall complication rate is measured by number of participants who experienced overall complications (including instrumentation fracture, cage subsidence, revision surgery, and wound breakdown/infection)

    Time frame: 3 years following surgery

  12. Percentage of participants reporting functional outcomes as measured by PROMIS-29

    Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: Baseline (Pre-op)

  13. Percentage of participants reporting functional outcomes as measured by PROMIS-29

    Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: 6 weeks following surgery

  14. Percentage of participants reporting functional outcomes as measured by PROMIS-29

    Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: 3 months following surgery

  15. Percentage of participants reporting functional outcomes as measured by PROMIS-29

    Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: 6 months following surgery

  16. Percentage of participants reporting functional outcomes as measured by PROMIS-29

    Percentage of participants reporting functional outcomes is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire which contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).

    Time frame: 12 months following surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2026, 27 months after the start.

Of 204 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 27 months is above that.

Counting every sponsor, half of 216 studies reached it within 12 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Feb 5, 2024
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05762055
Collaborators
Medtronic
Responsible party
Salah Aoun (ASSISTANT PROFESSOR, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Mar 9, 2023
Start date
Feb 5, 2024
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
May 13, 2026

Study contacts

Salah Aoun, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion